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Abstract
We conducted a systematic review and meta-analysis to assess the effects of increasing dietary omega-3, omega-6 and mixed 
polyunsaturated fatty acids (PUFA) on musculoskeletal health, functional status, sarcopenia and risk of fractures. We searched 
Medline, Embase, The Cochrane library, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform 
(ICTRP) databases for Randomised Controlled Trials (RCTs) of adults evaluating the effects of higher versus lower oral 
omega-3, omega-6 or mixed PUFA for ≥ 6 months on musculoskeletal and functional outcomes. We included 28 RCTs (7288 
participants, 31 comparisons), 23 reported effects of omega-3, one of omega-6 and four of mixed total PUFA. Participants and 
doses were heterogeneous. Six omega-3 trials were judged at low summary risk of bias. We found low-quality evidence that 
increasing omega-3 increased lumbar spine BMD by 2.6% (0.03 g/cm2, 95% CI − 0.02 to 0.07, 463 participants). There was 
also the suggestion of an increase in femoral neck BMD (of 4.1%), but the evidence was of very low quality. There may be 
little or no effect of omega-3 on functional outcomes and bone mass; effects on other outcomes were unclear. Only one study 
reported on effects of omega-6 with very limited data. Increasing total PUFA had little or no effect on BMD or indices of fat-
free (skeletal) muscle mass (low-quality evidence); no data were available on fractures, BMD or functional status and data on 
bone turnover markers were limited. Trials assessing effects of increasing omega-3, omega-6 and total PUFA on functional 
status, bone and skeletal muscle strength are limited with data lacking or of low quality. Whilst there is an indication that 
omega-3 may improve BMD, high-quality RCTs are needed to confirm this and effects on other musculoskeletal outcomes.
Keywords Fatty acids omega-3 · Musculoskeletal physiological phenomena · Bone density · Muscle strength · Fatty 
acids omega-6 · Fatty acids unsaturated · Meta-analysis · Randomised controlled trial · Aged · Alpha-linolenic acid · 
Docosahexaenoic acids · Eicosapentaenoic acid
Introduction
Decline in musculoskeletal health presents a significant risk 
to functional ability for older individuals, with concomitant 
reduction in quality of life, greater demand on health and 
social care services and higher risk of mortality. Sarcopenia 
(loss of skeletal muscle mass and strength), loss of bone 
mass and structural integrity (osteopenia or osteoporosis) are 
common in later life and are partially inter-dependent [1, 2], 
with each contributing to increased frailty, physical disabil-
ity, risk of falls and fractures [3, 4]. Loss of bone mass starts 
in adults around 30 to 40 years of age and women in the 
post-menopausal decade experience a particularly high rate 
of decline. Men also experience progressive, albeit smaller, 
loss of bone mass [5]. Loss of skeletal muscle mass and 
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function and the development of sarcopenia follow similar 
trajectories to bone [6]. Together sarcopenia and fractures 
have high prevalence and economic burden [7, 8]. This is 
predicted to increase so that by 2045, 13% to 22% of those 
aged > 65 years in Europe will be sarcopenic [9], and 20% 
of women and 5% of men aged > 50 years will have osteo-
porosis. Currently, approximately half of women and a fifth 
of men over the age of 60 years will experience an osteo-
porotic fracture [7]. As the number of individuals aged ≥ 60 
is expected to double worldwide by 2050 [10] develop-
ment and implementation of effective strategies to reduce 
the global burden of musculoskeletal decline is critical to 
avoid unsustainable demands on future health and social care 
systems. Dietary intervention to reduce or delay musculo-
skeletal decline may represent a relatively easily achievable 
component of such strategies, and thus it is of particular 
public health importance to further our understanding of 
how nutritional factors contribute to musculoskeletal health 
during ageing.
Dietary fat is important to normal muscle structure and 
function. Fatty acids act as a key substrate for ATP produc-
tion and thus provide a major energy source during aerobic 
exercise [11], as well as being key structural components of 
the sarcolemma (muscle cell membrane). Several mecha-
nisms have been proposed for omega-3 and omega-6 poly-
unsaturated fatty acids (PUFA) in musculoskeletal health 
[12–14]. These include PUFA-induced maintenance of anti-
oxidant-oxidant balance, preventing the oxidative stress that 
can lead to skeletal muscle atrophy; omega-6-induced acti-
vation of transcription factor peroxisome proliferator acti-
vator receptor gamma (PPARγ), which inhibits osteoblast 
growth, negatively affecting bone remodelling [15]; omega-3 
effects on increasing calcium absorption, by modulating cal-
cium-ATPase when levels are low [16]; PUFAs promoting 
osteoblastic differentiation through increased production of 
IGF-1 and parathyroid hormone and omega-3 FAs causing 
downregulation of chemicals involved in osteoclastic growth 
[13, 17].
Overall, omega-3 is suggested to exhibit protective effects 
on bone and muscle whilst omega-6 is thought to have pro-
inflammatory effects with detrimental consequences to 
musculoskeletal health. Thus, a higher omega-3: omega-6 
ratio is proposed as beneficial. This is supported by studies 
showing populations with high omega-3: omega-6 ratios, 
such as the Japanese or Inuit, have lower rates of osteoporo-
sis than populations with lower omega-3: omega-6 dietary 
ratios [18].
Previous systematic reviews evaluating the effects of 
omega-3, omega-6 or total PUFA on skeletal muscle and 
bone health, sarcopenia or fracture risk have been limited to 
specific PUFAs (usually omega-3) [19–22], specific popu-
lation subgroups (e.g. post-menopausal women) [19] or 
specific outcomes (e.g. bone markers or osteoporosis) [23] 
and most did not meta-analyse. Effects of total PUFA have 
not been investigated recently [24]. There is thus a need for 
a comprehensive review of omega-3, omega-6 and mixed 
PUFAs on bone and skeletal muscle health or functional 
status, in order to inform public health nutritional policy for 
musculoskeletal health in older individuals. We therefore 
undertook this systematic review to assess effects of increas-
ing dietary omega-3, omega-6 or mixed total PUFA on key 
musculoskeletal outcomes and functional status in adults 
aged 40 years or older.
Methods
We conducted the review following methods recommended 
by The Cochrane Handbook and reported the process and 
results in accordance with the preferred reporting items for 
systematic reviews and meta-analyses (PRISMA) statement 
[25, 26]. This review was part of a set of reviews evaluating 
the effects of PUFAs on various health outcomes [27–34]; 
detailed methods are reported elsewhere [35]. The methods 
reported below are those specific to this review.
Selection Criteria
We included randomised controlled trials (RCTs) that com-
pared higher versus lower omega-3, omega-6 or mixed 
PUFA (i.e. providing both omega-3 and omega-6), over a 
period of at least 24 weeks. We included studies reported as 
full text, trials registry entries and conference abstracts. Par-
ticipants included healthy adults and those at risk of or diag-
nosed with sarcopenia and/or osteopenia, aged ≥ 40 years 
(where ≥ 90% of participants were aged ≥ 40 years or where 
data could be separated out for those aged ≥ 40). Studies 
of pregnant women or acutely ill patients were excluded. 
Participants with non-acute co-morbidities were included 
except where the co-morbidity was likely to affect fatty acid 
absorption or musculoskeletal outcomes (e.g. coeliac dis-
ease, cystic fibrosis, systemic lupus erythematosus, rheuma-
toid arthritis, ulcerative colitis and Crohn’s Disease).
Interventions had to aim to increase or decrease omega-
3, omega-6 and/or total PUFA intakes, or achieve ≥ 10% 
increase or decrease from baseline. Interventions could 
include dietary supplementation (oils, capsules, enriched 
foods or naturally rich food sources given by mouth), or 
provided diet or dietary advice. Multifactorial interventions 
(with exercise, smoking cessation, medications or other 
dietary aims) were excluded unless the effect of change in 
PUFA could be separated out from other interventions. The 
control group had to have lower PUFA intake (including 
usual diet; no advice; no supplementation; placebo or an 
intervention aiming at lowering PUFA intake). Primary out-
comes included:
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• For bone fracture incidence, any measure of BMD, e.g. 
bone mineral density (BMD), bone mineral content 
(BMC) or total bone mass.
• For muscle sarcopenia or dynapenia (age-associated loss 
of muscle strength) incidence, skeletal muscle mass.
• For functional status mobility scores or other validated 
functional status measures, e.g. Barthel Index or Activi-
ties of Daily Living (ADL).
Secondary outcomes included direct measures of muscle 
strength or physical performance (e.g. grip strength, gait 
speed), fracture risk score, osteoporosis or osteopenia inci-
dence and bone turnover markers. A study was eligible for 
inclusion if it assessed any primary or secondary outcome.
Search Methods for Identification of Studies
We identified studies using complex and extensive search 
strategies and duplicate assessment as described else-
where [35], creating a database of trials that randomised 
participants to increased omega-3, omega-6 or total PUFA 
compared to lower omega-3, omega-6 or total PUFA and 
assessed effects over at least 24 weeks. From the database, 
studies were chosen for this review that had assessed any pri-
mary or secondary outcome (even when not fully reported). 
Reference lists of all included primary studies and relevant 
systematic reviews were hand-searched for additional 
references.
Data Collection and Assessment of Risk of Bias
Two reviewers independently assessed inclusion, extracted 
data (characteristics, methods and results data) and assessed 
risk of bias. Risk of bias was assessed using the Cochrane 
Risk of Bias tool [36]. A trial was considered to be at low 
summary risk of bias where randomisation, allocation con-
cealment, blinding of participants and personnel and blind-
ing of outcome assessors were all judged adequate [35]. We 
tried to contact authors where inclusion could not be ascer-
tained, where outcomes were measured but not reported or 
not reported in a usable format.
Data Synthesis
Our primary analyses assessed effects of total PUFA, 
omega-6, omega-3 on our primary outcomes. Treatment ver-
sus control differences in outcomes were combined across 
studies where appropriate using relative risks (RR) or mean 
differences (MD) in random-effects meta-analysis (using 
Review Manager Version 5.3; The Nordic Cochrane Centre, 
The Cochrane Collaboration, Copenhagen, Denmark). The 
random-effects model was used since dietary interventions 
are heterogeneous. Change from baseline was preferred; 
however, we used end data where change data were not 
reported or reported with no variance. Where different scales 
measured the same outcome we ensured all scales worked 
in the same direction (inverting where necessary), before 
combining data using standardised mean differences (SMD). 
For SMDs, 0.2 represented little or no effect, 0.5 a moderate 
effect and 0.8 a large effect. Where a representative study at 
low summary risk of bias was included in the meta-analysis, 
we translated the pooled SMD back into the scale used in 
that trial to help understand effect sizes.
Subgroup analyses were planned to explore the effects 
of the long-chain omega 3 (LCn-3) EPA (eicosapentaenoic 
acid) and DHA (docosahexaenoic acid), their precursor 
alpha linoleic acid (ALA), omega-6 and mixed PUFA intake 
on primary outcomes where at least ten RCTs reported a 
single comparison. Planned subgroup analyses included gen-
der, baseline risk of osteoporosis/skeletal muscle loss (gen-
eral population; those at higher risk, e.g. post-menopausal 
women, early menopause, 65+ , family history; those with 
osteopenia/sarcopenia; those with diagnosed osteoporosis), 
intervention type, trial duration, baseline LCn-3, ALA, 
omega-6 or total PUFA intake [35]. Sensitivity analyses 
were carried out to assess the effects of methodological 
rigour (including only studies with a low summary risk of 
bias), study size and fixed effects meta-analysis. Funnel plots 
were planned to explore potential reporting biases for the 
primary outcomes where we included ≥ 10 studies in single 
meta-analyses.
The GRADE (Grading of Recommendations, Assess-
ment, Development and Evaluations) framework was used 
to assess strength of evidence across studies for primary 
outcomes. Outcome data were interpreted as usual for this 
set of reviews [35]. RR < 0.92 or > 1.08 was considered an 
effect, whilst change from baseline of ≥ 5% was required for 
continuous measures except for cumulative measures such as 
BMD and adiposity (where a change of ≥ 2% was required). 
This 2% change compares with changes of 0.4% annual 
decrease in BMD in older adults and the 5% decrease with 
3% annual decreases in grip strength in older adults [37].
Results
Study flow from 37,810 titles and abstracts generated by 
electronic searches through to our database of 363 RCTs 
of at least 6 months duration comparing higher with lower 
omega-3, omega-6 and/or total PUFA intake has been 
detailed previously [35]. Of the 363 RCTs in the database 28 
RCTs (7288 participants, 31 comparisons) met our inclusion 
criteria, of which 25 RCTs (27 comparisons) contributed to 
meta-analyses (see Fig. 1 for the flow diagram). Characteris-
tics of these 28 included studies are summarised in Table 1, 
full details are in the database [35]. Fourteen included RCTs 
 A. Abdelhamid et al.
1 3
Fig. 1  Study flow diagram
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were conducted in Europe, four in North America, four each 
in Asia and Australia and one each for South America and 
Africa. Eight RCTs included only post-menopausal women 
[22, 38–46], two of which were of osteopenic or osteoporo-
tic women [22, 43]. Sample sizes ranged from 25 to 2501 
(mean 252, median 100 participants), and intervention dura-
tion ranged from 24 weeks to 4 years (mean 12.9 months).
Twenty-three studies were omega-3 interventions, of 
which 21 provided LCn-3 (EPA and/or DHA) and two 
provided ALA [39, 40]. Effects of increasing mixed total 
PUFA was evaluated by three studies [38, 43, 47, 48], whilst 
omega-6 was assessed in by one [49]. The intervention was 
supplementary capsules in 23 studies with the remaining 
five providing supplementary oils, nuts or seeds [39, 40, 47, 
48, 50, 51]. No studies provided dietary advice only. Doses 
ranged from 0.4 to 5.8 g/d LCn-3 and 3.5 to 9.1 g/d ALA. 
The omega-6 study provided 0.48 g/d GLA and two mixed 
PUFA studies provided ~ 4.5 g/d (PUFA dose was unclear 
in one study).
Data from three studies could not be used in the meta-
analysis. EPOCH and Sinn did not report numerical data 
for functional outcomes [52, 53], whilst OmegAD only 
provided arm muscle circumference as medians and inter-
quartile range [54]. Six included RCTs, assessing effects of 
omega-3 [46, 53, 55–59], were judged to be at low summary 
risk of bias (Fig. 2).
Effects of Higher Omega‑3
GRADE assessment of quality of evidence is shown in 
Table 2, and the meta-analysis results in Additional Table 1. 
No studies reported data on BMC, sarcopenia, dynapenia or 
myopenia incidence.
Fractures
The effect of increasing omega-3 fats on fracture incidence 
is unclear as the evidence is of very low quality (downgraded 
once for risk of bias, twice for imprecision). One RCT [42] 
reported the incidence of one fracture (RR 0.16, 95% CI 0.01 
to 3.91, 126 participants).
Bone Density
Increasing omega-3 intake may have little or no effect on 
total bone mass, with data available from one small study 
[60]. Total bone mass increased < 2% from baseline (0.2 kg, 
95% CI − 2.8 to 3.2). Evidence was of low quality, down-
graded once each for risk of bias (the study was not at low 
summary risk of bias) and imprecision (as the 95% CI 
included both important benefits and harms).
Fig. 2  Risk of bias summary for each included study
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Bone Mineral Density (BMD)
Effects of increasing omega-3 fats on proximal femur BMD 
are unclear as the evidence is of very low-quality down-
graded once for indirectness, twice for imprecision. Increas-
ing omega-3 may slightly increase lumbar spine BMD by 
2.6% (MD 0.03 g/cm2, 95% CI − 0.02 to 0.07, 463 par-
ticipants, low-quality evidence, downgraded once each for 
inconsistency and imprecision) and femoral neck BMD by 
4.1% (MD 0.04 g/cm2, 95% CI 0.0 to 0.08, 463 participants, 
very low-quality evidence, downgraded once each for risk 
of bias, inconsistency and imprecision). Four omega-3 stud-
ies (5 comparisons, of which 4 were in post-menopausal 
women) reported effects on BMD (Fig. 3). There was little 
or no effect of omega-3 on BMD at any site when sensi-
tivity analyses were limited to RCTs at low summary risk 
of bias (Additional Table 1). We ran a post hoc sensitivity 
analysis limiting to the three studies of at least 1 year (as 
BMD changes slowly). This led to losing the effect on lum-
bar spine BMD (MD 0.00 g/cm2, 95% CI − 0.04 to 0.04, 
384 participants) and decreasing the effect shown on femo-
ral neck BMD (MD 0.01 g/cm2, 95% CI 0.0 to 0.02, 384 
participants).
As the same studies reported BMD at several sites, 
SMD was not used to combine results.
Skeletal Muscle Mass
The effect of increasing omega-3 fats on skeletal muscle 
mass is unclear as the evidence is of a very low quality. 
Indices of skeletal muscle mass were reported in nine stud-
ies as percentage, percentage change or in kilograms, so 
we used SMD to combine measures, suggesting a small 
statistically significant improvement in indices muscle 
mass with higher omega-3 and a small-to-moderate effect 
size (Fig. 4). The evidence was undermined by high het-
erogeneity (SMD 0.38, 95% CI 0.05 to 0.70, 7 studies, 476 
participants,  I2 67%), risk of bias (as no included studies 
were at low summary risk of bias) and indirectness (meas-
ures varied between studies). We identified one study with 
missing data [54] which reported slightly higher median 
arm muscle circumference in the omega-3 arm compared 
to control (change of − 0.1 cm in males and + 0.1 cm in 
females, compared to − 0.3 cm in placebo for males and 
females combined).
Fig. 3  Effect of high versus low omega-3 on BMD at different sites
 A. Abdelhamid et al.
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Functional Status
Increasing omega-3 may have little or no effect on func-
tional status (low-quality evidence, downgraded once each 
for indirectness and publication bias). Ten RCTs measured 
functional status using various scales, of which eight pre-
sented numerical results of which one presented means with-
out variance. We used SMD to combine the remaining seven 
RCTs [9 comparisons, SMD-0.04, 95% CI − 0.11, 0.02,  I2 
0% (Fig. 5)]. This SMD equates to little or no effect, and 
using MAPT Short Physical Performance Battery Score to 
re-express SMD suggests MD 0.08 equates to 0.7% increase 
from baseline on the SPPB scale. The three studies without 
usable data suggested non-statistically significant effects [53, 
58] or provided no data [52].
Secondary Outcomes
Measures of Physical Performance/Strength
Two studies reported measures of handgrip strength (% 
change or kg), neither was at low summary risk of bias. 
Combining these using SMD did not suggest a statistically 
significant effect of increased omega-3. Other measures 
Fig. 4  Effect of high versus low omega-3 on various measures of skeletal muscle mass in different sites
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assessed within the two RCTs included leg extensor power, 
walking speed and repeated chair rises, but no single meas-
ure was reported by both studies. These two studies sug-
gested improvement in the measures used with high omega-3 
PUFA and combining data from the two studies using SMD 
suggested a positive effect of high omega-3 PUFA on physi-
cal performance (SMD 0.47, 95% CI 0.09, 0.85, 161 partici-
pants,  I2 17%).
Bone formation markers were reported in three studies, 
none of which was at low summary risk of bias. One study 
author provided raw data that allowed inclusion in the meta-
analysis [22]. Osteocalcin was the most frequently reported 
marker (3 studies, 4 comparisons, with heterogeneous data, 
 I2 55%) suggesting a small increase with increased omega-
3. There was little or no effect on other markers (Additional 
Table 1).
Fig. 5  Effect of high versus low omega-3 on various measures of functional status
 A. Abdelhamid et al.
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Bone resorption markers were reported in four studies 
[22, 42, 45, 46]; C-terminal telopeptide of type 1 collagen 
(CTX) was reported in two studies (3 comparisons) whilst 
N-telopeptide of type 1 collagen (NTX) and urinary total 
pyridinoline (PYD) in one study each. There was a sugges-
tion of a decrease of CTX with increased omega-3, and an 
increase in urinary PYD, but these were non-statistically 
significant, and from small studies. Only the smallest trial 
was at low summary risk of bias and suggested no effect of 
omega-3 on CTX.
Various other markers of bone turnover were reported 
with parathyroid hormone being the most commonly 
reported (3 RCTs, 4 comparisons) with no significant effect 
of high omega-3 (Additional Table 1).
Effects of Omega‑6
Primary Outcomes
No omega-6 studies reported on any primary outcome, so 
GRADE assessment was not carried out. Meta-analysis 
results are shown in Additional Table 2.
Secondary Outcomes
The only included omega-6 study [49] used GLA supple-
mentation, randomised 84 participants and was not at low 
summary risk of bias. It provided data on two outcomes 
related to physical performance measures, arm and leg mus-
cle strength, using scales of 0 to 2500 or 2000, respectively, 
suggesting little or no effect. The paper is unclear about 
whether higher or lower scores indicated greater strength, 
though both measures suggested small statistically signifi-
cant increases (Additional Table 2).
Effects of Mixed Total PUFA
GRADE assessment of quality of evidence is shown in 
Table 3, and meta-analysis results in Additional Table 3.
Primary Outcomes
No trials assessing effects on fracture incidence, total bone 
mass, BMC, sarcopenia, dynapenia or myopenia incidence 
or measures of functional status were identified.
Bone Density
Increasing total PUFA may have little or no effect on BMD 
(low-grade evidence, downgraded once each for risk of bias 
and indirectness). Three mixed PUFA studies reported BMD 
as an outcome (Fig. 6), but no two studies reported on the 
same site (total, femoral neck, lumbar or calcaneal reported). 
Combining the three trials across sites (allowing one entry 
from the study with multiple measures) suggested little or 
no effect (< 2% change from baseline). For individual sites, 
there was a suggestion that increasing total PUFA increased 
femoral neck BMD (MD 0.07 g/cm2, 95% CI 0.03 to 0.1, 1 
RCT, 60 participants), but there were no suggested effects at 
any other site. No studies were at low summary risk of bias.
Skeletal Muscle Mass
Increasing total PUFA may have little or no effect on fat-free 
mass (downgraded once each for risk of bias and indirect-
ness). Fat-free mass was reported in one study [50] with 
214 participants, and change from baseline was < 2% (MD 
− 0.5 kg, 95% CI − 1.63 to 0.63).
Secondary Outcomes
No included trial reporting secondary outcomes was at low 
summary risk of bias.
Measures of Physical Performance/Strength
Only one small UK study of healthy post-menopausal 
women [38] at moderate-to-high summary risk of bias 
reported a small non-significant decline in leg extensor 
power in the mixed PUFA intervention group compared to 
the control (MD − 8 W, 95% CI − 23.8–7.8, 42 participants).
Bone Turnover Markers
Bone formation markers were reported in three studies, 
none at low summary risk of bias, with little or no effect for 
all except a suggestion of a reduction in C1NP with higher 
PUFA (Additional Table 3). Osteocalcin was reported by all 
three studies suggesting little or no effect (MD 0.52 μg/L, 
95%CI − 1.99–0.95, 195 participants,  I2 45%). Serum bone-
specific alkaline phosphatase was reported in all three stud-
ies, but one study reported it as a percentage (so could not 
be combined). There was no significant effect on either 
measure. Other markers reported by a single study included 
serum type 1 procollagen and procollagen.
Various markers of bone resorption were reported in three 
studies, but none were at low summary risk of bias. All sug-
gested little or no effect except that there were small non-sta-
tistically significant falls of NTX/CR and CTX and urinary 
hydroxyproline with higher PUFA intake. The deoxypyri-
dinoline/creatinine ratio was the only marker reported in 
two studies, other markers were reported by single studies. 
Parathyroid hormone was the most frequently reported bone 
turnover marker, reported by three studies. Pooled results 
suggested a small non-statistically significant increase in 
parathyroid hormone with increased PUFA.
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Discussion
We have systematically reviewed the long-term effects of 
omega-3, omega-6 and total PUFA supplementation on 
risk factors for sarcopenia and fracture: functional status, 
bone density and skeletal muscle mass. We identified and 
included 28 RCTs (31 comparisons, 7288 participants), of 
which six were at low summary risk of bias. Twenty-three 
studies reported on the effects of increasing omega-3 fatty 
acids, but effects were unclear (as the evidence was of very 
low quality) for fracture incidence, total proximal femur 
BMD and skeletal muscle mass. Low or very low-quality 
data suggested that increasing omega-3 may increase lum-
bar spine and femoral neck BMD but has little or no effect 
on total bone mass or measures of functional status. A few 
small trials suggested increases in physical performance and 
osteocalcin with increased omega-3 but data were of limited 
quality. The single eligible study on omega-6 did not report 
on any primary outcomes, and was not at low summary risk 
of bias. As far as it could be interpreted, this study suggested 
little or no effect on arm and leg muscle strength of omega-6. 
Three RCTs (4 comparisons) assessed effects of increasing 
mixed total PUFA and none were at low summary risk of 
bias. None reported on fracture incidence, total bone mass 
or measures of functional status. The existing data suggested 
that increasing total PUFA may have little or no effect on 
BMD (when effects at different sites were combined) or fat-
free mass. Data on secondary outcomes were very limited 
but suggested reductions in leg extensor power, C1NP, NTX/
CR, CTX and urinary hydroxyproline, and a small increase 
in parathyroid hormone with more PUFA. There was con-
siderable heterogeneity in populations studied and doses of 
fatty acids supplemented.
Observational data have suggested positive associations 
between intake of total PUFAs, total omega-6 and total 
omega-3 and BMD [61, 62]. This systematic review sug-
gests that increasing omega-3 has little or no effect on func-
tional status, though it may increase BMD a little. There 
is some evidence from reviews of shorter duration trials 
that omega-3 improves skeletal muscle outcomes [21] and 
decreases osteocalcin [19]. However, if such effects are not 
maintained over the longer term their utility is very limited.
To our knowledge, this is the first systematic review to 
evaluate all PUFA interventions on both bone and skeletal 
muscle health as well as functional status, important risk 
factors for sarcopenia, osteoporosis and increased fragil-
ity fractures. This review included trials irrespective of 
whether their primary aim was to assess skeletal muscle 
or bone outcomes. This allowed us to evaluate effects of 
PUFA supplementation on various measures of sarcopenia. 
Fig. 6  Effect of high versus low mixed PUFA on BMD in different sites
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This was beneficial as sarcopenia has been poorly defined 
until recently [63, 64], and no studies assessed sarcopenia 
as a diagnosis. Our review excluded studies with multi-
factorial or multi-supplement interventions. Although this 
limited the evidence base used, it ensures that any effects 
seen are specifically related to PUFA supplementation. Our 
minimum intervention period was 24 weeks, as previous 
studies have suggested this length of time is the minimum 
required to allow equilibration of most body compartments 
with an altered fatty acid balance, and allow time for bone 
and muscle changes to become detectable [65, 66]. Limita-
tions included limited numbers of relevant trials, and limited 
numbers of trials at low summary risk of bias. Whilst we 
excluded studies in individuals with overt clinical conditions 
that may influence the metabolism and utilisation of unsatu-
rated fatty acids, not all studies described the proportion of 
individuals with, for instance, type 2 diabetes. Whilst the 
presence of type 2 diabetes may influence the results of sup-
plementation studies with PUFA, we were unable to quantify 
these effects in the data available. This, along with heteroge-
neous results, has led to the evidence produced being of low 
or very low quality so overall the evidence to address effects 
of omega-3, omega-6 and total PUFA on functional, muscle 
and bone outcomes is limited. The inclusion of all PUFA 
nutritional interventions regardless of their nature (i.e. sup-
plemental, food provision or dietary advice) could be viewed 
as a limitation restricting the comparability of the results, 
however, all interventions in the included studies aimed to 
increase one or more PUFA.
Despite the limitations of our study due to the lack of 
comprehensive evidence from trials with low risk of bias, 
thus limiting the conclusions from our study the importance 
of PUFA on musculoskeletal heath and outcomes deserves 
further research. The lack of studies relating greater intakes 
of PUFA to risk factors for sarcopenia is due to the relatively 
recent recognition and evolving definitions for this condition 
[64] as well as to the combination of exercise and dietary 
interventions which means it is not possible to isolate the 
effects of PUFA intake alone.
Recommendations for future research include larger-
scale studies in populations likely to have low intakes as 
well as circulating concentrations of EPA and DHA. ALA 
interventions are also unlikely to be effective in those 
already consuming high concentrations of EPA and DHA 
due to their competition with ALA as substrates for the 
desaturase, elongase pathway responsible for conversion 
from ALA to EPA and then DHA [67]. So these studies 
should be limited to populations consuming small quan-
tities of EPA and DHA. Future studies determining the 
effects of omega-3 PUFA on BMD would require a dura-
tion of 12 months or longer to enable detection of measur-
able changes and the intervention to be of sufficient scale 
to detect the effects these interventions. We also recom-
mend taking baseline measurements of intake and circulat-
ing concentrations of PUFA. Reporting from trials should 
also include the proportion of individuals with metabolic 
conditions such as type 2 diabetes that may impact on the 
utilisation and metabolism of PUFA.
In conclusion, we found low-quality evidence that 
omega-3 may increase BMD by a small amount, but there 
were no other clear effects of omega-3 or total PUFA on 
skeletal muscle, bone or functional outcomes. Evidence of 
the effects of omega-6 supplementation on bone or skeletal 
muscle outcomes was insufficient to warrant any conclu-
sions. Further trials assessing effects of omega-3, omega-6 
and mixed PUFA on musculoskeletal outcomes are war-
ranted, but only if the trials are methodologically strong 
(at low summary risk of bias) and appropriately powered.
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